We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00669903
Recruitment Status : Terminated (Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to stop further development of AZD0328)
First Posted : May 1, 2008
Results First Posted : August 6, 2010
Last Update Posted : August 6, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: AZD0328 Drug: Placebo Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Oral Multiple Ascending Doses of AZD0328 in Patients With Schizophrenia
Study Start Date : April 2008
Primary Completion Date : November 2008
Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
AZD0328 low dose
Drug: AZD0328
Experimental: 2
AZD0328 Optimal dose
Drug: AZD0328
Experimental: 3
AZD0328 High dose
Drug: AZD0328
Placebo Comparator: 4
Placebo Comparator
Drug: Placebo


Outcome Measures

Primary Outcome Measures :
  1. CogState Groton Maze Learning Task (GMLT) and One Card Learning Task (OCLT) Standardized Composite Score at Day 14 [ Time Frame: Baseline and Day 14 ]
    The GMLT and OCLT standardized change composite score will be calculated as the mean of the GMLT and OCLT standardized change from baseline scores. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate. Scale range from negative infinity (worst value) to positive infinity (best value).


Secondary Outcome Measures :
  1. CogState Groton Maze Learning Task (GMLT) Standardized Change Score at Day 14 [ Time Frame: Baseline and Day 14 ]
    GMLT score is defined as the -log10 transform of the sum of the number of errors made during GMLT trials. Mean GMLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMLT standardized change score was calculated as the change from baseline in the mean GMLT score divided by the within subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).

  2. CogState One Card Learning Task (OCLT) Standardized Change Score at Day 14 [ Time Frame: Baseline and Day 14 ]
    OCLT score is defined as the arcsine transform of the proportion of correct responses during OCLT trials. Mean OCLT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The OCLT standardized change score was calculated as the change from baseline in the mean OCLT score divided by the within-subject standard deviation. Scale range from negative infinity (worst value) to positive infinity (best value).

  3. CogState Detection Task (DT) Standardized Change Score at Day 14 [ Time Frame: Baseline and Day 14 ]
    DT score is defined as -1 times the mean of log10 transformed reaction times for all correct responses. Mean DT score was calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The DT standardized change score will be calculated as the change from baseline in the mean DT score divided by the within-subject standard deviation. Score range from negative infinity (worst value) to positive infinity (best value).

  4. CogState Identification Task (IT) Standardized Change Score at Day 14 [ Time Frame: Baseline and Day 14 ]
    IT score defined as 1 times the mean of log10 transformed reaction times for all correct responses. Mean IT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The IT standardized change score will be calculated as the change from baseline in the mean IT score divided by the within-subject standard dev. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, and assessment day-by-treatment interaction as fixed factors, center as a random factor, and baseline score as a covariate

  5. CogState Groton Maze Recall Task (GMRT) Standardized Change Score at Day 14 [ Time Frame: Baseline and Day 14 ]
    GMRT score defined as the -log10 transform of the sum of the number of errors made during GMRT trials. Mean GMRT score calculated as the average of the 2 hour, 5 hour, and 8 hour scores. The GMRT standardized change score was calculated as change from baseline in mean GMRT score divided by the within subject standard deviation. Least square means were derived using a mixed effects repeated measures model with protocol scheduled assessment day, treatment group, baseline score, assessment day-by-treatment interaction as fixed factors, center as random factor, and baseline score as a covariate


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition)
  • Low level of Extra-pyramidal symptoms
  • No clinically significant findings on physical examination

Exclusion Criteria:

  • Diagnosis of schizoaffective or schizophreniform disorders
  • Any significant psychiatric or neurological disease other than schizophrenia
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00669903


Locations
United States, California
Research Center
Garden Grove, California, United States
Research Center
Glendale, California, United States
Sponsors and Collaborators
AstraZeneca
More Information

Responsible Party: Didier Meulien - Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT00669903     History of Changes
Other Study ID Numbers: D0190C00007
First Posted: May 1, 2008    Key Record Dates
Results First Posted: August 6, 2010
Last Update Posted: August 6, 2010
Last Verified: July 2010

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders